Edity Therapeutics
Edity is an Israel-based company developing a novel delivery platform that uses immune cells to transfer therapeutic proteins to the target cells of patients. Their technology allows for precise modulation of intracellular pathways of disease using a range of proteins including gene editors, immune sensors, enzymes and intrabodies.
DegRx / Proxygen
Proxygen is a Vienna-based startup that develops therapies against cancer and other life-threatening diseases by reprogramming the cellular protein quality control system. We are focused on particular small molecules called “molecular glue degraders” which mediate recruitment of a disease-causing protein to a ubiquitin ligase. Consequently, the target protein is ubiquitinated and directed to the proteasome […]
Ayoxxa Biotech
AYOXXA Biosystems GmbH, based in Cologne (Germany), is an international biotech company focused on the development of its proprietary beads-on-a-chip technology for advanced protein analysis. LUNARIS™. AYOXXA’s innovative multiplex protein analysis platform is a fully integrated system designed for the parallel analysis of multiple biomarkers in picogram amounts of biological samples, allowing scientists to gain […]
